Bradley’s impressive track record includes serving as lead counsel for a Fortune 100 technology company and an Ivy League university in major antitrust litigations, and co-leading the Axinn teams defending Google and Tyson Foods in headline-making antitrust litigations. He helped Momenta Pharmaceuticals resolve a dispute over its generic blood thinner enoxaparin, achieving a favorable outcome following an earlier trial loss, prior to Axinn’s involvement.

Bradley also maintains a robust practice focused on securing antitrust clearances for major mergers. Notably, he was a lead advisor for The Dow Chemical Company’s $130 billion merger with DuPont — one of the largest and most complex merger reviews in history, requiring approvals in over 20 jurisdictions worldwide.

Bradley has been widely recognized for his work in complex antitrust matters. He was named a “Rising Star” by both Law360 and The National Law Journal, and in 2025, he received Global Competition Review’s “Lawyer of the Year – Under 40” award, following a prior shortlisting in 2022. He is ranked in Chambers USA and The Legal 500, and has been named to Benchmark Litigation’s “40 & Under” list in both 2023 and 2024. In addition, Lawdragon recognizes him as a “Leading Global Competition & Antitrust Lawyer” and one of the “500 Leading Litigators in America.”